Beating GOLIATH

The incidence of obesity and metabolic disorders such as diabetes and non-alcoholic fatty liver disease has reached ‘Goliathan’ proportions. There is strong evidence that exposures to chemicals present in our environment contribute to these diseases. This project aims to ‘beat Goliath’ by better understanding how these chemicals work and developing new methods to test chemicals for metabolism disrupting effects.

What are metabolism disrupting chemicals?

MDCs are natural or anthropogenic chemicals that that have the ability to promote metabolic changes that can ultimately result in obesity, diabetes and/or fatty liver in humans. Four main targets tissues of MDCs will be studied in GOLIATH, namely adipose tissue, liver, pancreas and muscle.

Towards an integrated approach to testing and assessment of MDCs

Currently there are no regulatory tests to assess how and to what extent chemicals disrupt metabolism, leading to metabolic disorders. By developing and combining data from in silico and in vitro assays, animal and human studies, the aim of GOLIATH is to develop an integrated, internationally harmonised approach for testing and assessment.

Partners in GOLIATH

GOLIATH is an international consortium consisting of 15 partners from 8 European countries and the United States.

News

MORE NEWS

Events